close X
Patient Portal

Macular Degeneration Clinical Trials

Macular Degeneration Clinical TrialsRetina Specialty Institute is a renowned ophthalmology practice that proudly serves patients across Northwest Florida, Central Florida, Mississippi, and the Alabama Gulf Coast. Our esteemed, skilled eye doctors provide transformative retina care in all aspects of service—from personalized treatments to advanced techniques to state-of-the-art surgical procedures. RSI is the trusted partner of countless people across the US looking to protect and enhance their vision. As part of our commitment to continued advancement and innovation in the ophthalmology field and eye/retina treatment, our practice offers clinical trials on an ongoing basis. Learn more about our current Macular Degeneration clinical trials below and contact us now for any questions or to book an appointment with a physician. You may also visit our clinical trials FAQ page for commonly asked questions and answers.


Macular Degeneration - DRY

Astellas 7317-CL-0003
A Staged Study Incorporating A Phase 1b, Multicenter, Unmasked, Dose Escalation Evaluation Of Safety And Tolerability And A Phase 2, Multicenter, Unmasked, Randomize, Parallel-Group, Controlled, Proof Of Concept Investigation Of Efficacy And Safety Of ASP7317 For Atrophy Secondary To Age-Related Macular Degeneration
Sponsor: Astellas Institute for Regenerative Medicine
Retina Specialty Institute PI: Sunil Gupta, MD
Clinicaltrials.gov
Status: Open to enrollment

Apellis APL2-304
A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Sponsor: Apellis Pharmaceuticals, Inc.
Retina Specialty Institute PI: Sunil Gupta, MD
Clinicaltrials.gov
Status: Open to enrollment

GR 40973
A Phase II, Multi-Center, Randomized, Single-Masked, Sham Injection-Controlled Study of the Safety, Tolerability, and Evidence of Activity of Intravitreal Injection of RO7171009 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Sponsor: Genentech, Inc.
Retina Specialty Institute PI: Sunil Gupta, MD
Status: Open to enrollment

Macular Degeneration - WET

Portal GR40549
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration
Sponsor: Genentech, Inc.

Retina Specialty Institute PI: Sunil Gupta, MD
Clinicaltrials.gov
Status: Open to enrollment

Merlin CRTH258AUS04
A Multicenter, Randomized, Double-Masked Phase 3a Study to Assess Safety and Efficacy of Brolucizumab 6mg Q4W Compared to Aflibercept 2mg Q4W in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Persistent Retinal Fluid
Sponsor: Novartis Pharmaceuticals
Retina Specialty Institute PI: Sunil Gupta, MD
Clinicaltrials.gov
Status: Open to enrollment

Tenaya GR40306
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration
Sponsor: Genentech, Inc.

Retina Specialty Institute PI: Sunil Gupta, MD
Clinicaltrials.gov
Status: Open to enrollment

Graybug GBV-102-002
A Phase 2b, Multi-Center, Dose-Ranging Study Evaluating the Safety and Efficacy of a Long-Acting Intravitreal Sunitinib Malate Depot Formulation (GB-102) Compared to Intravitreal Aflibercept in Subjects with Neovascular (Wet) Age-Related Macular Degeneration
Sponsor: Graybug Vision
Retina Specialty Institute PI: Sunil Gupta, MD
Clinicaltrials.gov
Status: Not yet enrolling

PanOptica PAN-01-102
A Randomized, Double Masked, Uncontrolled, Multicenter Phase I/II Study To Evaluate Safety And Tolerability Of PAN-90806 Eye Drops, Suspension In Treatment- Naïve Participants With Neovascular Age-Related Macular Degeneration (AMD)
Sponsor: PanOptica, Inc.
Retina Specialty Institute PI: Sunil Gupta, MD
Clinicaltrials.gov
Status: Closed to enrollment

Archway GR40548
A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System in Patients with Neovascular Age-Related Macular Degeneration
Sponsor: Genentech, Inc.

Retina Specialty Institute PI: Sunil Gupta, MD
Clinicaltrials.gov
Status: Closed to enrollment

It’s Time to See...

The Difference Visionary Retina Care Makes